HomeTrading IdeasEurozone Inflation Lands Right...

Eurozone Inflation Lands Right at ECB Target in June

The in the eurozone ticked up slightly to 2% on higher energy prices, but remained stable at 2.3%. Inflationary pressures have clearly weakened as wage growth is coming down and economic performance remains sluggish, keeping the door open to another rate cut in autumn

The slight increase in inflation in June is not going to cause much excitement for anyone. It’s strange to say in a global economy experiencing huge uncertainty, but eurozone inflation has become delightfully dull again.

Most importantly, services inflation experienced barely any bounce back after an unusually low reading in May. Package holiday prices fell in May on the back of fewer public holidays and likely bounced back somewhat in June, but softness in the services sector means that the overall services inflation rate only ticked up from 3.2 to 3.3%.

Goods inflation fell from 0.6 to 0.5%, generally indicating that despite supply chain distortions in recent months, demand remains too weak to cause immediate consumer price pressures. In fact, surveys indicate weakening selling price expectations among goods manufacturers since May.

Overall, the domestic inflation environment is expected to remain benign. Wage growth has fallen markedly over recent quarters. We expect it to trend around 3% at the end of the year, which is consistent with inflation at the 2% target now that productivity is picking back up.

Risks of inflation spikes are not hard to spot in the current global economy. Think of the recent spike, for example, or possible retaliatory tariffs by the European Commission if negotiations with the US fail next week. But the underlying picture is one that shows inflation around target, thanks to moderating wage growth and sluggish economic growth for the foreseeable future.

Disclaimer: This publication has been prepared by ING solely for information purposes irrespective of a particular user’s means, financial situation or investment objectives. The information does not constitute investment recommendation, and nor is it investment, legal or tax advice or an offer or solicitation to purchase or sell any financial instrument. Read more

Original Post

Most Popular

More from Author

CAD/JPY Ready to Continue Rising Ahead of Employment Change and Unemployment Rate

For three months since April, the currency has shown strength...

What’s Going On With Hims & Hers Health Stock On Monday? – Hims & Hers Health (NYSE:HIMS)

Hims & Hers Health, Inc. HIMS is currently experiencing a decline...

Why Is Cogent Biosciences Stock Trading Higher On Monday? – Cogent Biosciences (NASDAQ:COGT)

Cogent Biosciences, Inc.‘s COGT bezuclastinib showed meaningful clinical benefit for patients with...

3 Bullish Setups to Watch in July Amid Seasonal Tailwinds

As the second half of the year begins, several bullish setups...

Read Now

CAD/JPY Ready to Continue Rising Ahead of Employment Change and Unemployment Rate

For three months since April, the currency has shown strength against the . although at the moment the price still cannot break the small resistance area on the H4 timeframe. but it is expected that the fundamental impulses can move the market more significantlyFigure 1. CAD/JPY...

What’s Going On With Hims & Hers Health Stock On Monday? – Hims & Hers Health (NYSE:HIMS)

Hims & Hers Health, Inc. HIMS is currently experiencing a decline in its stock price, trading lower on Monday. The company’s stock has plummeted approximately 18% over the past month, reflecting recent challenges.A significant development contributing to this decline occurred in June 2025, when Novo Nordisk A/S...

Why Is Cogent Biosciences Stock Trading Higher On Monday? – Cogent Biosciences (NASDAQ:COGT)

Cogent Biosciences, Inc.‘s COGT bezuclastinib showed meaningful clinical benefit for patients with non-advanced systemic mastocytosis, a rare and debilitating immune disorder. With statistically significant improvements across all endpoints—including symptom reduction and biomarkers of mast cell activity—the data support the company's plan to file for Food and Drug Administration...

3 Bullish Setups to Watch in July Amid Seasonal Tailwinds

As the second half of the year begins, several bullish setups are emerging—each supported by seasonal patterns and historical data. is approaching multi-year highs following a strong June, while technical signals in the broader market and semiconductor sector point to continued momentum. Meanwhile, recent policy developments may...

The Energy Report: Listen to What OPEC Says

prices are shaking off a larger-than-expected OPEC production increase as the precious metals get hit by a ton of bricks after President Trump posted about new tariffs on BRIC Nations on his Truth Social account. Yet despite the talk about OPEC wanting to maintain its market share,...

Why Is KalVista Pharmaceuticals Stock Soaring On Monday? – KalVista Pharma (NASDAQ:KALV)

The U.S. Food and Drug Administration (FDA) on Monday approved KalVista Pharmaceuticals Inc.’s KALV Ekterly (sebetralstat) for acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.Ekterly is the first and only oral on-demand treatment for HAE. HAE is characterized by recurrent...

Dow Jones Forecast: Political Tensions and Tariff Risks Weigh on Outlook

US futures are rising on Monday after the extended holiday weekend. Uncertainty surrounding U.S. trade tariff policies are keeping investors cautious, whilst Tesla (NASDAQ:) is taking a hit after Musk announced plans to launch a political party.US Futures 0.78% at 44839 0.7% at 6266 0.53% at 23977In...

Why Is Apogee Therapeutics Stock Soaring On Monday? – Apogee Therapeutics (NASDAQ:APGE)

Apogee Therapeutics Inc. APGE stock is experiencing a significant surge, trading almost 29% higher in premarket on Monday.This substantial increase in stock price follows the release of positive 16-week data from Part A of the Phase 2 APEX clinical trial of APG777, an anti-IL-13 antibody, for moderate-to-severe...

EUR/USD Slips as Trade Talks Stall and Retail Sales Disappoint

falls with trade talks in focus and following weak retail sales. Oil slips after OPEC+ increases output by more than expected.EUR/USD Falls With Trade Talks in Focus and After Weak Retail SalesThe EU and the US are nearing a framework agreement Eurozone retail sales fell -0.7% MoM EUR/USD...

Oil Prices Expected to Stay Under $70

Analysts widely expect oil prices to remain below $70 per barrel for the remainder of 2025, primarily due to global oversupply and ongoing uncertainties regarding demand. Despite heightened geopolitical tensions in the Middle East, these factors are not anticipated to significantly drive up oil prices unless direct supply...

Markets Await Trade Deals as Trump Makes New Tariff Threats

Dollar edges higher, gold slips despite confusion and renewed trade tensions Trump delays tariff deadline to August 1, says trade deals are close Wall Street hits record after Congress passes Big Beautiful Bill Oil recovers from lows after OPEC+ hikes output more than expected New Threats and ExtensionsThe dreaded July 9...

Gold Prices Under Pressure as Tariff Talks Offset Geopolitical Risks

Tariff Negotiations Weigh Down on Gold Gold () rose slightly on Friday as markets adjusted amid evolving trade headlines. However, it pulled back during the day as traders monitored negotiations with key U.S. trade partners, many aiming to finalise deals or secure more time ahead of approaching deadlines....